NEW YORK / Feb 13, 2025 / Business Wire / DocGo Inc. (Nasdaq: DCGO) (“DocGo” or the “Company”), a leading provider of technology-enabled mobile health services, announced today that the Company will release its financial results for the fourth quarter and full year ended December 31, 2024 after the markets close on Thursday, February 27, 2025. Management will also host a conference call to discuss these results at 5:00 p.m. ET on that day.
Conference call and webcast details:
Thursday, February 27, 2025
5:00 p.m. ET
1-800-717-1738 (U.S.)
1-646-307-1865 (international)
Conference ID: 41220
To access the Call me™ feature, which avoids the need to wait for an operator, click here.
A webcast of the conference call can be accessed under Events on the Investors section of the Company’s website at https://ir.docgo.com/.
About DocGo
DocGo is leading the proactive healthcare revolution with an innovative care delivery platform that includes mobile health services, remote patient monitoring and medical transport solutions. DocGo is helping to reshape the traditional four-wall healthcare system by providing high quality, highly accessible care to patients where and when they need it. DocGo’s proprietary technology and relationships with a dedicated field staff of certified health professionals elevate the quality of patient care and drive business efficiencies for facilities, hospital networks and health insurance providers. With Mobile Health, DocGo empowers the full promise and potential of telehealth by facilitating healthcare treatment, in tandem with a remote physician, in the comfort of a patient’s home or workplace. Together with DocGo’s integrated Ambulnz medical transport services, DocGo is bridging the gap between physical and virtual care. For more information, please visit www.docgo.com. To get an inside look on how the proactive healthcare revolution is helping transform healthcare by reducing costs, increasing efficiency and improving outcomes, visit www.proactivecarenow.com.
Last Trade: | US$1.50 |
Daily Change: | -0.06 -3.85 |
Daily Volume: | 588,526 |
Market Cap: | US$148.650M |
May 08, 2025 February 27, 2025 February 19, 2025 |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREChimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREEnd of content
No more pages to load